To validate the mRNA and protein levels of CPVL in glioma tissues of different grades, we conducted quantitative PCR (qPCR) and Western blotting in the low-grade (WHO I/II) and high-grade (WHO III/IV) glioma groups. This evidence concerns the gene CPVL and central nervous system cancer.